|
1
|
International Agency for Research on
Cance: GLOBOCAN 2012: estimated cancer incidence, mortality and
prevalence worldwide in 2012. World Health Organization. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
Accessed Sept 2, 2014.
|
|
2
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parameswaran R, Brooks S and Sadler GP:
Molecular pathogenesis of follicular cell derived thyroid cancers.
Int J Surg. 8:186–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barakate DM: Thyroid cancer prognosis.
Thyroid Clinic Sydney. http://www.thyroid.com.au/thyroid-cancer/thyroid-cancer-prognosis/2015.
Accessed Sept 3. 2015.
|
|
7
|
Conzo G, Docimo G, Mauriello C,
Gambardella C, Esposito D, Cavallo F, Tartaglia E, Napolitano S and
Santini L: The current status of lymph node dissection in the
treatment of papillary thyroid cancer. A literature review Clin
Ter. 164:e343–e346. 2013.
|
|
8
|
Cooper DS, Doherty GM, Haugen BR, Kloos
RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F,
Schlumberger M, et al American Thyroid Association (ATA) Guidelines
Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer:
Revised American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hall TL, Layfield LJ, Philippe A and
Rosenthal DL: Sources of diagnostic error in fine needle aspiration
of the thyroid. Cancer. 63:718–725. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moses W, Weng J, Sansano I, Peng M,
Khanafshar E, Ljung BM, Duh QY, Clark OH and Kebebew E: Molecular
testing for somatic mutations improves the accuracy of thyroid
fine-needle aspiration biopsy. World J Surg. 34:2589–2594. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krause K, Jessnitzer B and Fuhrer D:
Proteomics in thyroid tumor research. J Clin Endocrinol Metab.
94:2717–2724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang
S, Fan Y, Yang H, Wu P, Yu J, et al: Discovery and identification
of potential biomarkers of papillary thyroid carcinoma. Mol Cancer.
8:79–93. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown LM, Helmke SM, Hunsucker SW,
Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW and
Haugen BR: Quantitative and qualitative differences in protein
expression between papillary thyroid carcinoma and normal thyroid
tissue. Mol Carcinog. 45:613–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giusti L, Iacconi P, Ciregia F,
Giannaccini G, Donatini GL, Basolo F, Miccoli P, Pinchera A and
Lucacchini A: Fine-needle aspiration of thyroid nodules: Proteomic
analysis to identify cancer biomarkers. J Proteome Res.
7:4079–4088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Subhasitanont P, Srisomsap C, Punyarit P
and Svasti J: Proteomic studies of galectin-3 expression in human
thyroid diseases by immunodetection. Cancer Genomics Proteomics.
3:389–394. 2006.
|
|
16
|
Srisomsap C, Subhasitanont P, Otto A,
Mueller EC, Punyarit P, Wittmann-Liebold B and Svasti J: Detection
of cathepsin B up-regulation in neoplastic thyroid tissues by
proteomic analysis. Proteomics. 2:706–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Griffith OL, Chiu CG, Gown AM, Jones SJ
and Wiseman SM: Biomarker panel diagnosis of thyroid cancer: A
critical review. Expert Rev Anticancer Ther. 8:1399–1413. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feilchenfeldt J, Tötsch M, Sheu S-Y,
Robert J, Spiliopoulos A, Frilling A, Schmid KW and Meier CA:
Expression of galectin-3 in normal and malignant thyroid tissue by
quantitative PCR and immunohistochemistry. Mod Pathol.
16:1117–1123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Volante M, Bozzalla-Cassione F, Orlandi F
and Papotti M: Diagnostic role of galectin-3 in follicular thyroid
tumors. Virchows Arch. 444:309–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kebebew E, Peng M, Reiff E and McMillan A:
Diagnostic and extent of disease multigene assay for malignant
thyroid neoplasms. Cancer. 106:2592–2597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scognamiglio T, Hyjek E, Kao J and Chen
Y-T: Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1
and evaluation of their expression in encapsulated lesions with
questionable features of papillary thyroid carcinoma. Am J Clin
Pathol. 126:700–708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Viglietto G and De Marco C: Molecular
biology of thyroid cancer. Contemporary Aspects of Endocrinology.
Diamanti-Kandarakis E: InTech; c2011, pp. 189–234. 2011, http://www.intechopen.com/books/contemporary-aspects-of-endocrinology/molecular-biology-of-thyroid-cancer.
|
|
23
|
Schlumberger MJ: Papillary and follicular
thyroid carcinoma. N Engl J Med. 338:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zaydfudim V, Feurer ID, Griffin MR and
Phay JE: The impact of lymph node involvement on survival in
patients with papillary and follicular thyroid carcinoma. Surgery.
144:1070–1077; discussion 1077–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woyach JA and Shah MH: New therapeutic
advances in the management of progressive thyroid cancer. Endocr
Relat Cancer. 16:715–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morita N, Ikeda Y and Takami H: Clinical
significance of p53 protein expression in papillary thyroid
carcinoma. World J Surg. 32:2617–2622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grogan RH, Mitmaker EJ and Clark OH: The
evolution of biomarkers in thyroid cancer-from mass screening to a
personalized biosignature. Cancers (Basel). 2:885–912. 2010.
View Article : Google Scholar
|
|
28
|
Kim JW and Dang CV: Multifaceted roles of
glycolytic enzymes. Trends Biochem Sci. 30:142–150. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Capello M, Ferri-Borgogno S, Cappello P
and Novelli F: α-Enolase: A promising therapeutic and diagnostic
tumor target. FEBS J. 278:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mikuriya K, Kuramitsu Y, Ryozawa S,
Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I and
Nakamura K: Expression of glycolytic enzymes is increased in
pancreatic cancerous tissues as evidenced by proteomic profiling by
two-dimensional electrophoresis and liquid chromatography-mass
spectrometry/mass spectrometry. Int J Oncol. 30:849–855.
2007.PubMed/NCBI
|
|
31
|
Zhang XZ, Xiao ZF, Li C, Xiao ZQ, Yang F,
Li DJ, Li MY, Li F and Chen ZC: Triosephosphate isomerase and
peroxiredoxin 6, two novel serum markers for human lung squamous
cell carcinoma. Cancer Sci. 100:2396–2401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang YS, Wu W, Walsh G, Hong WK and Mao
L: Enolase-α is frequently down-regulated in non-small cell lung
cancer and predicts aggressive biological behavior. Clin Cancer
Res. 9:3641–3644. 2003.PubMed/NCBI
|
|
33
|
Liu K-J and Shih N-Y: The role of enolase
in tissue invasion and metastasis of pathogens and tumor cells. J
Cancer Mol. 3:pp. 45–48. 2007, http://www.mupnet.com/jocm%203%282%29%2045-48.pdf.
|
|
34
|
Liaudet-Coopman E, Beaujouin M, Derocq D,
Garcia M, Glondu-Lassis M, Laurent-Matha V, Prébois C, Rochefort H
and Vignon F: Cathepsin D: Newly discovered functions of a
longstanding aspartic protease in cancer and apoptosis. Cancer
Lett. 237:167–179. 2006. View Article : Google Scholar
|
|
35
|
Dunn AD, Crutchfield HE and Dunn JT:
Proteolytic processing of thyroglobulin by extracts of thyroid
lysosomes. Endocrinology. 128:3073–3080. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kraimps J-L, Métayé T, Millet C, Margerit
D, Ingrand P, Goujon JM, Levillain P, Babin P, Begon F and Barbier
J: Cathepsin D in normal and neoplastic thyroid tissues. Surgery.
118:1036–1040. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lokman NA, Ween MP, Oehler MK and
Ricciardelli C: The role of annexin A2 in tumorigenesis and cancer
progression. Cancer Microenviron. 4:199–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mussunoor S and Murray GI: The role of
annexins in tumour development and progression. J Pathol.
216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bao H, Jiang M, Zhu M, Sheng F, Ruan J and
Ruan C: Overexpression of Annexin II affects the proliferation,
apoptosis, invasion and production of proangiogenic factors in
multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sidani M, Wessels D, Mouneimne G, Ghosh M,
Goswami S, Sarmiento C, Wang W, Kuhl S, El-Sibai M, Backer JM, et
al: Cofilin determines the migration behavior and turning frequency
of metastatic cancer cells. J Cell Biol. 179:777–791. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang W, Eddy R and Condeelis J: The
cofilin pathway in breast cancer invasion and metastasis. Nat Rev
Cancer. 7:429–440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu B, Fukada K, Zhu H and Kyprianou N:
Prohibitin and cofilin are intracellular effectors of transforming
growth factor β signaling in human prostate cancer cells. Cancer
Res. 66:8640–8647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maiti AK, Ghosh K, Chatterjee U,
Chakrobarti S, Chatterjee S and Basu S: Epidermal growth factor
receptor and proliferating cell nuclear antigen in astrocytomas.
Neurol India. 56:456–462. 2008. View Article : Google Scholar
|
|
44
|
Cvejic D, Selemetjev S, Savin S, Paunovic
I and Tatic S: Changes in the balance between proliferation and
apoptosis during the progression of malignancy in thyroid tumours.
Eur J Histochem. 53:65–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feng L, Li M, Zhang Q-P, Piao Z-A, Wang
Z-H and Lv S: Utility of BRAF protein overexpression in predicting
the metastasis potential of papillary thyroid carcinoma. Oncol
Lett. 2:59–63. 2011.PubMed/NCBI
|
|
46
|
Tomsig JL, Sohma H and Creutz CE:
Calcium-dependent regulation of tumour necrosis factor-alpha
receptor signalling by copine. Biochem J. 378:1089–1094. 2004.
View Article : Google Scholar
|
|
47
|
Tomsig JL, Snyder SL and Creutz CE:
Identification of targets for calcium signaling through the copine
family of proteins. Characterization of a coiled-coil
copine-binding motif. J Biol Chem. 278:10048–10054. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ramsey CS, Yeung F, Stoddard PB, Li D,
Creutz CE and Mayo MW: Copine-I represses NF-kappaB transcription
by endoproteolysis of p65. Oncogene. 27:3516–3526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Parcellier A, Gurbuxani S, Schmitt E,
Solary E and Garrido C: Heat shock proteins, cellular chaperones
that modulate mitochondrial cell death pathways. Biochem Biophys
Res Commun. 304:505–512. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Garrido C, Brunet M, Didelot C, Zermati Y,
Schmitt E and Kroemer G: Heat shock proteins 27 and 70:
Anti-apoptotic proteins with tumorigenic properties. Cell Cycle.
5:2592–2601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lebret T, Watson RWG, Molinié V, O'Neill
A, Gabriel C, Fitzpatrick JM and Botto H: Heat shock proteins
HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma.
Cancer. 98:970–977. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Paoli P, Giannoni E and Chiarugi P:
Anoikis molecular pathways and its role in cancer progression.
Biochim Biophys Acta. 1833:3481–3498. 2013. View Article : Google Scholar : PubMed/NCBI
|
